Cost-utility of a multicomponent intervention for fibromyalgia versus usual care: a pragmatic randomised controlled trial

Authors

  • Victoria Mailen Arfuch Terres de l'Ebre Research Support Unit, Jordi Gol I Gurina Primary Health Research Institute Foundation (IDIAPJGol), Tortosa, Spain; Department of Pediatrics, Obstetrics and Gynecology, and Preventive Medicine and Public Health, Autonomous University of Barcelona, Bellaterra, Spain; Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden https://orcid.org/0000-0001-5935-6907
  • Carina Aguilar Martín Terres de l'Ebre Research Support Unit, Jordi Gol I Gurina Primary Health Research Institute Foundation (IDIAPJGol), Tortosa, Spain; Evaluation Unit, Directorate of Primary Care Terres de l'Ebre, Territorial Management of Terres de l'Ebre, Catalan Institute of Health (ICS), Tortosa, Spain https://orcid.org/0000-0002-2357-5726
  • Anna Berenguera Department of Pediatrics, Obstetrics and Gynecology, and Preventive Medicine and Public Health, Autonomous University of Barcelona, Bellaterra, Spain; Central Research Unit, Jordi Gol I Gurina Primary Health Research Institute Foundation (IDIAPJGol), Barcelona, Spain; Department of Nursing, University of Girona, Plaça de Sant Domènec, Girona, Spain https://orcid.org/0000-0002-0889-2002
  • Rosa Caballol Angelats Primary Care Center (CAP) El Temple, Territorial Management of Terres de l’Ebre, Catalan Health Institute (ICS), Tortosa, Spain; Unit of Expertise in Central Sensitization Syndromes Terres de l'Ebre, Territorial Management of Terres de l'Ebre, Catalan Institute of Health (ICS), Tortosa, Spain https://orcid.org/0000-0001-5780-9888
  • Alessandra Queiroga Gonçalves Terres de l'Ebre Research Support Unit, Jordi Gol I Gurina Primary Health Research Institute Foundation (IDIAPJGol), Tortosa, Spain; Tortosa, Spain, 9Family and Community Medicine Teaching Unit Tortosa-Terres de L’Ebre, Catalan Institute of Health (ICS), Tortosa, Spain https://orcid.org/0000-0003-3272-6861
  • Noèlia Carrasco-Querol Terres de l'Ebre Research Support Unit, Jordi Gol I Gurina Primary Health Research Institute Foundation (IDIAPJGol), Tortosa, Spain https://orcid.org/0000-0002-5876-7082
  • Gemma González Serra Rehabilitation and Physical Medicine Service, Tortosa Verge de la Cinta Hospital, Territorial Management of Terres de l'Ebre, Catalan Health Institute (ICS), Tortosa, Spain https://orcid.org/0000-0001-5720-9049
  • Maria Cinta Sancho Sol Unit of Expertise in Central Sensitization Syndromes Terres de l'Ebre, Territorial Management of Terres de l'Ebre, Catalan Institute of Health (ICS), Tortosa, Spain; Adult Mental Health Center (CSMA) of Fundació Pere Mata Terres de l’Ebre, Tortosa, Spain https://orcid.org/0000-0001-9221-7028
  • Immaculada Fusté Anguera Primary Care Center (CAP) El Temple, Territorial Management of Terres de l’Ebre, Catalan Health Institute (ICS), Tortosa, Spain; Unit of Expertise in Central Sensitization Syndromes Terres de l'Ebre, Territorial Management of Terres de l'Ebre, Catalan Institute of Health (ICS), Tortosa, Spain https://orcid.org/0000-0002-1244-1108
  • Emilie Friberg Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden https://orcid.org/0000-0001-7874-4243
  • Emma Pettersson Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden https://orcid.org/0000-0002-4776-9162
  • Marc Casajuana Department of Pediatrics, Obstetrics and Gynecology, and Preventive Medicine and Public Health, Autonomous University of Barcelona, Bellaterra, Spain; Central Research Unit, Jordi Gol I Gurina Primary Health Research Institute Foundation (IDIAPJGol), Barcelona, Spain https://orcid.org/0000-0001-5653-996X

DOI:

https://doi.org/10.2340/jrm.v55.12361

Keywords:

cost-utility analysis, fribromyalgia syndrome, health economic evaluation, multicomponent intervention, primary care

Abstract

Objective: To perform an economic evaluation on a multicomponent intervention programme for patients with fibromyalgia syndrome compared with usual clinical practice in primary care.

Design: A cost-utility analysis was conducted alongside a pragmatic randomised controlled trial (ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/record/NCT04049006) from a societal perspective, a human capital approach, and a 1-year time horizon.

Patients: Patients diagnosed with fibromyalgia  syndrome from the public health system in south Catalonia, Spain.

Methods: Crude and adjusted incremental cost- utility ratios were estimated to compare the treatment strategies based on cost estimations (direct medical costs and productivity losses) and quality-adjusted life years. One-way and 2-way deterministic sensitivity analyses were performed.

Results: The final analysed sample comprised 297 individuals, 161 in the intervention group and 136 in the control group. A crude incremental cost-utility ratio of € 1,780.75 and an adjusted ratio of € 851.67 were obtained, indicating that the programme  significantly improved patients’ quality of life with a cost-increasing outcome that fell below the cost-effectiveness threshold. The sensitivity analysis  confirmed these findings when  varying large cost components, and showed dominance when increasing session attendance.

Conclusion: The proposed multicomponent intervention programme was cost-effective compared with usual care for fibromyalgia, which supports its addition to standard practice in the regional  primary care service.

Downloads

Download data is not yet available.

References

Giorgi V, Sirotti S, Romano ME, Marotto D, Ablin JN, Salaffi F, et al. Fibromyalgia: one year in review 2022. Clin Exp Rheumatol 2022; 40: 1065-1072.

https://doi.org/10.55563/clinexprheumatol/if9gk2 DOI: https://doi.org/10.55563/clinexprheumatol/if9gk2

Wolfe F, Walitt B, Perrot S, Rasker JJ, Häuser W. Fibromyalgia diagnosis and biased assessment: sex, prevalence and bias. PLoS One 2018; 13: 1-14.

https://doi.org/10.1371/journal.pone.0203755 DOI: https://doi.org/10.1371/journal.pone.0203755

Pasqual Marques A, Espírito Santo A de S, Berssaneti AA, Matsutani LA, King Yuan SL. Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol 2017; 57: 356-363. DOI: https://doi.org/10.1016/j.rbre.2017.01.005

https://doi.org/10.1016/j.rbr.2016.10.004 DOI: https://doi.org/10.1016/j.rbr.2016.10.004

Font Gayà T, Bordoy Ferrer C, Juan Mas A, Seoane-Mato D, Álvarez Reyes F, Delgado Sánchez M, et al. Prevalence of fibromyalgia and associated factors in Spain. Clin Exp Rheumatol 2020; 38: 47-52.

Ursini F, Ciaffi J, Mancarella L, Lisi L, Brusi V, Cavallari C, et al. Fibromyalgia: a new facet of the post- COVID-19 syndrome spectrum? Results based survey from a web-based survey. RMD Open 2021; 7: e001735.

https://doi.org/10.1136/rmdopen-2021-001735 DOI: https://doi.org/10.1136/rmdopen-2021-001735

Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-172.

https://doi.org/10.1002/art.1780330203 DOI: https://doi.org/10.1002/art.1780330203

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010; 62: 600-610.

https://doi.org/10.1002/acr.20140 DOI: https://doi.org/10.1002/acr.20140

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016; 46: 319-329.

https://doi.org/10.1016/j.semarthrit.2016.08.012 DOI: https://doi.org/10.1016/j.semarthrit.2016.08.012

de Tommaso M, Vecchio E, Nolano M. The puzzle of fibromyalgia between central sensitisation syndrome and small fiber neuropathy: a narrative review on neurophysiological and morphological evidence. Neurol Sci 2022; 43: 1667-1684.

https://doi.org/10.1007/s10072-021-05806-x DOI: https://doi.org/10.1007/s10072-021-05806-x

Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009; 11: 117.

https://doi.org/10.1186/ar2715 DOI: https://doi.org/10.1186/ar2715

Sicras-Mainar A, Rejas J, Navarro R, Milagrosa B, Morcillo A, Larios R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009; 11: R54.

https://doi.org/10.1186/ar2673 DOI: https://doi.org/10.1186/ar2673

Rivera J, Rejas J, Esteve-Vives J, Vallejo MA, Grupo ICAF. Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain. Clin Exp Rheumatol 2009; 27: S39-S45.

Thompson JM, Luedtke CA, Oh TH, Shah ND, Long KH, King S, et al. Direct medical costs in patients with fibromyalgia: cost of illness and impact of a brief multidisciplinary treatment program. Am J Phys Med Rehabil 2011; 90: 40-46.

https://doi.org/10.1097/PHM.0b013e3181fc7ff3 DOI: https://doi.org/10.1097/PHM.0b013e3181fc7ff3

Vervoort VM, Vriezekolk JE, Olde Hartman TC, Cats HA, van Helmond T, van der Laan WH, et al. Cost of illness and illness perceptions in patients with fibromyalgia. Clin Exp Rheumatol 2016; 34: S74-S82.

Cabo-Meseguer A, Cerda-Olmedo G, Trillo-Mata JL. Fibromyalgia: Prevalence, epidemiologic profiles and economic costs. Med Clin (Barc) 2017; 149: 441-448. DOI: https://doi.org/10.1016/j.medcle.2017.10.011

https://doi.org/10.1016/j.medcli.2017.06.008 DOI: https://doi.org/10.1016/j.medcli.2017.06.008

Skaer TL. Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden. Pharmacoeconomics 2014; 32: 457-466.

https://doi.org/10.1007/s40273-014-0137-y DOI: https://doi.org/10.1007/s40273-014-0137-y

Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, FluB E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017; 76: 318-328.

https://doi.org/10.1136/annrheumdis-2016-209724 DOI: https://doi.org/10.1136/annrheumdis-2016-209724

Yin JH, Peng GS, Ro LS. Multidisciplinary approach to Fibromyalgia: What are we learning from updated evidence-based medicine? Acta Neurol Taiwan 2022 Jan 18 [online ahead of print].

Hernando-Garijo I, Jiménez-Del-Barrio S, Mingo-Gómez T, Medrano-De-La-Fuente R, Ceballos-Laita L. Effectiveness of non-pharmacological conservative therapies in adults with fibromyalgia: a systematic review of high-quality clinical trials. J Back Musculoskelet Rehabil 2022; 35: 3-20.

https://doi.org/10.3233/BMR-200282 DOI: https://doi.org/10.3233/BMR-200282

Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendonça VA, Henschke N, et al. Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia: a systematic review and meta-analysis. JAMA Intern Med 2021; 181: 104-112. https://doi:10.1001/jamainternmed.2020.5651

https://doi.org/10.1001/jamainternmed.2020.5651 DOI: https://doi.org/10.1001/jamainternmed.2020.5651

Cabral CMN, Miyamoto GC, Franco KFM, Bosmans JE. Economic evaluations of educational, physical, and psychological treatments for fibromyalgia: a systematic review with meta-analysis. Pain 2021; 162: 2331-2345.

https://doi.org/10.1097/j.pain.0000000000002233 DOI: https://doi.org/10.1097/j.pain.0000000000002233

Mccabe C. What is cost-utility analysis? 2009. [Accessed 15 Jun 2022]. Available from http://www.bandolier.org.uk/painres/download/whatis/What_is_cost-util.pdf

Luciano JV, Sabes-Figuera R, Cardenosa E, Peñarrubia-María MT, Fernández-Vergel R, García-Campayo J, et al. Cost-utility of a psychoeducational intervention in fibromyalgia patients compared with usual care: an economic evaluation alongside a 12-month randomised controlled trial. Clin J Pain 2013; 29: 702-711.

https://doi.org/10.1097/AJP.0b013e318270f99a DOI: https://doi.org/10.1097/AJP.0b013e318270f99a

Luciano JV, D'Amico F, Cerdà-Lafont M, Peñarrubia-María MT, Knapp M, Cuesta-Vargas AI, et al. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomised controlled trial. Arthritis Res Ther 2014; 16: 1-17.

https://doi.org/10.1186/s13075-014-0451-y DOI: https://doi.org/10.1186/s13075-014-0451-y

Feliu-Soler A, Borràs X, Peñarrubia-María MT, Peñarrubia-María MT, Knapp M, Cuesta-Vargas AI, et al. Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study). BMC Complement Altern Med 2016; 16: 1-16.

https://doi.org/10.1186/s12906-016-1068-2 DOI: https://doi.org/10.1186/s12906-016-1068-2

Pérez-Aranda A, D'Amico F, Feliu-Soler A, McCracken LM, Peñarrubia-María MT, Andrés-Rodríguez L, et al. Cost-utility of mindfulness-based stress reduction for fibromyalgia versus a multicomponent intervention and usual care: a 12-month randomized controlled trial (EUDAIMON Study). J Clin Med 2019; 8: 1068.

https://doi.org/10.3390/jcm8071068 DOI: https://doi.org/10.3390/jcm8071068

Luciano J V, D'Amico F, Feliu-Soler A, McCracken LM, Aguado J, Peñarrubia-María MT, et al. Cost-utility of group acceptance and commitment therapy for fibromyalgia versus recommended drugs: an economic analysis alongside a 6-month randomized controlled trial conducted in Spain (EFFIGACT Study). J Pain 2017; 18: 868-880.

https://doi.org/10.1016/j.jpain.2017.03.001 DOI: https://doi.org/10.1016/j.jpain.2017.03.001

D'amico F, Feliu-Soler A, Montero-Marín J, Peñarrubía-María MT, Navarro-Gil M, Van Gordon W, et al. Cost-utility of attachment-based compassion therapy (ABCT) for fibromyalgia compared to relaxation: a pilot randomised controlled trial. J Clin Med 2020; 9: 726.

https://doi.org/10.3390/jcm9030726 DOI: https://doi.org/10.3390/jcm9030726

Caballol Angelats R, Gonçalves AQ, Aguilar Martín C, Sol MCS, Serra GG, Casajuana M, et al. Effectiveness, cost-utility, and benefits of a multicomponent therapy to improve the quality of life of patients with fibromyalgia in primary care: a mixed methods study protocol. Med (United States) 2019; 98: e17289.

https://doi.org/10.1097/MD.0000000000017289 DOI: https://doi.org/10.1097/MD.0000000000017289

Jönsson B. Editorial: ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Heal Econ 2009; 10: 357-359.

https://doi.org/10.1007/s10198-009-0173-2

DOI: 10.1007/s10198-009-0173-2

https://doi.org/10.1007/s10198-009-0173-2 DOI: https://doi.org/10.1007/s10198-009-0173-2

Kobelt G. Health Economics: an Introduction to Economic Evaluation. Vol 314. Third Edit. (Office of Health Economics (OHE), ed.). OHE Monograph 2013.

Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B. Improving the reporting of pragmatic trials : an ex-tension of the CONSORT statement. BMJ 2008; 337: a2390.

https://doi.org/10.1136/bmj.a2390 DOI: https://doi.org/10.1136/bmj.a2390

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations. Value Heal 2022; 25: 3-9.

https://doi.org/10.1016/j.jval.2021.11.1351 DOI: https://doi.org/10.1016/j.jval.2021.11.1351

Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. Int J Nurs Stud 2013; 50: 587-592.

https://doi.org/10.1016/j.ijnurstu.2012.09.010 DOI: https://doi.org/10.1016/j.ijnurstu.2012.09.010

Rodríguez-Feijoó S, Rodríguez-Caro A. [Pharmaceutical copayment in Spain after the 2012 reform from the user's perspective. Evidence of inequity?] Gac Sanit 2021; 35: 138-144 (in Spanish).

https://doi.org/10.1016/j.gaceta.2019.09.009 DOI: https://doi.org/10.1016/j.gaceta.2019.09.009

Celaya M, Ibáñez D, Laseca N, López A, Romero C, Valls E. Guia per a l'avaluació de la fibromiàlgia i de la síndrome de fatiga crònica. Barcelona: Direcció General d'Ordenació Professional i Regulació Sanitària; 2017. [accessed 2022 Jun 17]. Available from: http://hdl.handle.net/11351/5652

Catalunya G de. Diari Oficial de la Generalitat de Catalunya. [accessed 2022 Mar 15]. Available from: https://dogc.gencat.cat/es

World Health Organization (WHO). ICD-10: International Statistical Classification of Diseases and Related Health Problems: tenth revision. 2nd edn. Geneva: World Health Organization; 2004.

Efron B. Forcing a Sequential Experiment to be balanced. Biometrika 1971; 58: 403-417.

https://doi.org/10.1093/biomet/58.3.403 DOI: https://doi.org/10.1093/biomet/58.3.403

Alonso J. Versión española de SF-36v2TM Health Survey © 1996, 2000 adaptada por J. Alonso y cols 2003. Heal Surv Published online 2003: 1-8. [accessed 2020 Jan 10]. Available from: http://www.ser.es/wp-content/uploads/2015/03/SF36_CUESTIONARIOpdf.pdf

Rebollo P, Morís J, Ortega T, Valdés C, Ortega F. Estimating utility values for health status using the Spanish version of the SF-36. Validity of the SF-6D index vs EQ-5D. Med Clin (Barc) 2007; 128: 536-537.

https://doi.org/10.1157/13101163 DOI: https://doi.org/10.1157/13101163

Abellán-Perpiñán JM. Utilidades SF-6D Para España. Guía de Uso. Guía de uso 2012/8. Cátedra de Economía de la Salud. Universidad Pablo de Olavide. Sevilla: Consejería de Salud de la Junta de Andalucía; 2013.

Gisbert, R and Brosa M. Spanish health costs and cost-effectiveness ratios Database: eSalud Published 2007 [accessed 2022 Jun 30]. Available from: http://www.oblikue.com/bddcostes/

Ministerio de Sanidad de España. Boletín Oficial Del Estado Orden SND/1121/2020.; 2020 [accessed 2022 Jun 30]. Available from: https://www.boe.es/boe/dias/2020/11/28/pdfs/BOE-A-2020-15176.pdf

Instituto Nacional de Estadística.Coste laboral por trabajador, comunidad autónoma, sectores de actividad [Labor wages per worker, autonomous community, sectors of activity][accessed Nov 15, 2021]. Available from https://www.ine.es/jaxiT3/Tabla.htm?t=60611

Gobierno de España. Real Decreto 8/2015 por el que e aprueba el texto refundido de la Ley General de la Seguridad Social [Royal Decree 8/2015 approving the consolidated text of the General Social Security Law]. Boletín del Estado. Published online2015: 1-157 [accessed 2022 Mar 25]. Available from: http://www.boe.es/boe/dias/1994/06/29/pdfs/A20658-20708.pdf.

Seguridad Social España. Prestación de Incapacidad Temporal [Temporary disability benefits] [accessed 2022 Jun 30]. Available from: https://www.seg-social.es/wps/portal/wss/internet/InformacionUtil/44539/44667#:~:text=En general%2C el pago lo,INSS o de la mutua.

RStudio Team. RStudio: Integrated development environment for R. Published online 2022. Available from: http://www.rstudio.com/

Mantopoulos T, Mitchell PM, Welton NJ, McManus R, Andronis L. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results. Eur J Heal Econ 2016; 17: 927-938.

https://doi.org/10.1007/s10198-015-0731-8 DOI: https://doi.org/10.1007/s10198-015-0731-8

Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol 2008; 52: 2119-2126.

https://doi.org/10.1016/j.jacc.2008.09.018 DOI: https://doi.org/10.1016/j.jacc.2008.09.018

Andronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess 2009; 13: iii, ix-xi, 1-61.

https://doi.org/10.3310/hta13290 DOI: https://doi.org/10.3310/hta13290

Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol 2013; 13: 92.

https://doi.org/10.1186/1471-2288-13-92 DOI: https://doi.org/10.1186/1471-2288-13-92

Arfuch VM, Aguilar Martín C, Berenguera A, Caballol Angelats R, Carrasco-Querol N, Serra GG, et al. Cost-utility analysis of a multicomponent intervention for fibromyalgia syndrome in primary care versus usual clinical practice: study protocol for an economic evaluation of a randomised control trial. BMJ Open 2021; 11: e043562.

https://doi.org/10.1136/bmjopen-2020-043562 DOI: https://doi.org/10.1136/bmjopen-2020-043562

Vallejo MA, Rivera J, Esteve-Vives J, Rodríguez-Muñoz MF. [Use of the Hospital Anxiety and Depression Scale (HADS) to evaluate anxiety and depression in fibromyalgia patients]. Rev Psiquiatr Salud Ment 2012; 5: 107-114 (in Spanish).

https://doi.org/10.1016/j.rpsmen.2012.01.004 DOI: https://doi.org/10.1016/j.rpsmen.2012.01.004

Cabrera V, Martín-Aragón M, Terol MC, Nuñez R, Pastor MA. Hospital Anxiety and depression Scale (HADS) in fibromyalgia: sensitivity and specific analysis. Ter Psicológica 2015; 33: 181-193.

https://doi.org/10.4067/S0718-48082015000300003 DOI: https://doi.org/10.4067/S0718-48082015000300003

Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009; 11: R120.

https://doi.org/10.1186/ar2783 DOI: https://doi.org/10.1186/ar2783

Salgueiro M, García-Leiva JM, Ballesteros J, Hidalgo J, Molina R, Calandre EP. Validation of a Spanish version of the Revised Fibromyalgia Impact Questionnaire (FIQR). Health Qual Life Outcomes 2013; 11: 1-8.

https://doi.org/10.1186/1477-7525-11-132 DOI: https://doi.org/10.1186/1477-7525-11-132

Valls Llobet C. [Differential diagnosis of pain and fibromyalgia]. Anu Psicol Univ Barcelona 2008; 39: 87-92 (in Spanish).

Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ 2018; 27: 746-761.

https://doi.org/10.1002/hec.3633 DOI: https://doi.org/10.1002/hec.3633

Paulden M. Why it's time to abandon the ICER. Pharmacoeconomics 2020; 38: 781-784.

https://doi.org/10.1007/s40273-020-00915-5 DOI: https://doi.org/10.1007/s40273-020-00915-5

Paulden M. Calculating and interpreting ICERs and net benefit. Pharmacoeconomics 2020; 38: 785-807.

https://doi.org/10.1007/s40273-020-00914-6 DOI: https://doi.org/10.1007/s40273-020-00914-6

López Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, et al. [A proposed guideline for economic evaluation of health technologies]. Gac Sanit 2009; 24: 154-170 (in Spanish).

https://doi.org/10.1016/j.gaceta.2009.07.011 DOI: https://doi.org/10.1016/j.gaceta.2009.07.011

NICE. NICE Health Technology Evaluations: the manual (PMG36) 2022 [accessed 2022 Jul 2]. Available from: https://www.nice.org.uk/process/pmg36

Cavalli G, Cariddi A, Ferrari J, Suzzi B, Tomelleri A, Campochiaro C, et al. Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. Rheumatol 2021; 60: 465-467.

https://doi.org/10.1093/rheumatology/keaa738 DOI: https://doi.org/10.1093/rheumatology/keaa738

Schweiger V, Secchettin E, Perini G, Martini A, Donadello K, Gottin L, et al. Quality of life and psychological assessment in patients with fibromyalgia syndrome during COVID-19 pandemic in Italy : prospective observational study. Signa Vitae 2022; 18: 41-46.

Colas C, Jumel A, Vericel M, Barth N. Understanding experiences of fibromyalgia patients involved in the Fimouv study during COVID-19 lockdown Front Psuchol 2021; 12: 1-9.

https://doi.org/10.3389/fpsyg.2021.645092 DOI: https://doi.org/10.3389/fpsyg.2021.645092

Carrillo-de-la-Peña MT, González-Villar A, Triñanes Y. Effects of the COVID-19 pandemic on chronic pain in Spain : a scoping review. PAIN reports 2021; 6: e899.

https://doi.org/10.1097/PR9.0000000000000899 DOI: https://doi.org/10.1097/PR9.0000000000000899

Arfuch VM, Gonçalves AQ, Caballol Angelats R, Martín CA, Carrasco-Querol N, Sol MCS, et al. Patients' appraisals about a multicomponent intervention for fibromyalgia syndrome in primary care: a focus group study. Int J Qual Stud Health Well-being 2021; 16: 2005760.

https://doi.org/10.1080/17482631.2021.2005760 DOI: https://doi.org/10.1080/17482631.2021.2005760

O'Sullivan AK, Thompson D, Drummond MF. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value Health 2005; 8: 67-79.

https://doi.org/10.1111/j.1524-4733.2005.03065.x DOI: https://doi.org/10.1111/j.1524-4733.2005.03065.x

Downloads

Additional Files

Published

2023-12-19

How to Cite

Arfuch, V. M., Aguilar Martín, C., Berenguera, A., Caballol Angelats, R., Gonçalves, A. Q. ., Carrasco-Querol, N., … Casajuana, M. . (2023). Cost-utility of a multicomponent intervention for fibromyalgia versus usual care: a pragmatic randomised controlled trial. Journal of Rehabilitation Medicine, 55, jrm12361. https://doi.org/10.2340/jrm.v55.12361

Issue

Vol. 55 (2023)

Section

Original Report

Categories

License

Copyright (c) 2023 Victoria Mailen Arfuch, Carina Aguilar Martín, Anna Berenguera, Rosa Caballol Angelats, Alessandra Queiroga Gonçalves, Noèlia Carrasco-Querol, Gemma González Serra, Maria Cinta Sancho Sol, Immaculada Fusté Anguera, Emilie Friberg, Emma Pettersson, Marc Casajuana

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.

Crossref
Scopus
Google Scholar
Europe PMC

Funding data